Slight edit

LICENSE.md

@@ -1,7 +1,7 @@
 # AntiBERTa2 License 
 Version 1.0, December 2023 [Alchemab](http://alchemab.com)
 
-AntiBERTa2 models are antibody-specific Large Language Models (LLM) developed by Alchemab Therapeutics Ltd. Currently AntiBERTa2 includes the following two architectures referred to as AntiBERTa2 (202 M parameters) and AntiBERTa2-CSSP (202 M parameters). Based on the RoFormer LLM from natural language processing, AntiBERTa2 is pre-trained using MLM on 779.4 million unpaired and paired antibody sequences. AntiBERTa2-CSSP refers to a multimodal version of the AntiBERTa2 LLM that leverages the contrastive pre-training objective from the CLIP method; over 1000 antibody crystal structures from the Protein Data Bank were used. After pre-training, AntiBERTa2 develops a rich representation of antibody sequences that can be leveraged for an extensive range of tasks, including (without limitation) antigen binding prediction.
+AntiBERTa2 models are antibody-specific Large Language Models (LLM) developed by Alchemab Therapeutics Ltd. Currently AntiBERTa2 includes two architectures referred to as AntiBERTa2 (202 M parameters) and AntiBERTa2-CSSP (202 M parameters). Based on the RoFormer LLM from natural language processing, AntiBERTa2 is pre-trained using MLM on 779.4 million unpaired and paired antibody sequences. AntiBERTa2-CSSP refers to a multimodal version of the AntiBERTa2 LLM that leverages the contrastive pre-training objective from the CLIP method; over 1000 antibody crystal structures from the Protein Data Bank were used. After pre-training, AntiBERTa2 develops a rich representation of antibody sequences that can be leveraged for an extensive range of tasks, including (without limitation) antigen binding prediction.
 
 Alchemab Therapeutics is making AntiBERTa2, specifically its parameter weights, available for use, reproduction and distribution under this modified version of the Apache 2.0 Licence.